OptiNose (NSDQ:OPTN) raised $120 million with its initial public offering last week, adding $20 million to the target is set earlier this month. Yardley, Penn.-based OptiNose floated 7.5 million shares at $16 apiece in the offering, above the range it set Oct. 3 for 6.3 million shares at $15 to $17 apiece. The stock, trading on the […]
OptiNose sets terms for $100m IPO
OptiNose set terms for its IPO this week, according to a regulatory filing submitted to the SEC. The company plans to offer 6.3 million shares at $15 – $17 apiece and funds affiliated with Avista Capital Partners intend to buy $25 million worth of shares as part of the offering, according to OptiNose. The company […]
OptiNose registers $100m IPO
OptiNose has registered a $100 million initial public offering with the SEC to list its common stock on the Nasdaq market, according to a regulatory filing. The Yardley, Penn.-based company posted a net loss of -$16.3 million in the six months ended June 30, 2017 – down from a $34.3 million net profit during the […]
OptiNose wins FDA nod for Xhance nasal spray
OptiNose said today that the FDA approved its Xhance nasal spray for the treatment of nasal polyps in patients 18 years and older. The fluticasone propionate nasal spray is designed to deliver medication using OptiNose’s exhalation delivery system. The patient actuates the pump spray into one nostril while simultaneously blowing into the mouthpiece of the […]
OptiNose raises $37m in Series D for commercial efforts
OptiNose said today that it closed a $37 million Series D round led by Fidelity Management and Research Company. Avista Capital Partners, Entrepreneurs Fund and other current investors also contributed to the round. The Yardley, Penn.-based company said it plans to use the newly-acquired funds to support commercial development of its lead product candidate, OPN-375, […]
OptiNose touts Phase III data for exhaled breath drug delivery
OptiNose touted data from a pair of Phase III clinical trials proving the safety and efficacy of its exhaled breath drug delivery treatment for chronic rhinosinusitis patients with and without polyps. The company presented the data today at the American Rhinologic Society’s annual meeting in San Diego. Data from both trials showed limited adverse effects from […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn